National Investments Fund (01227) said it noted Celyad S.A., a company listed on Euronext in Europe and Nasdaq in the United States of America, announced the infusion of the first patient enrolled in the fourth dose level of its Phase I/IIa clinical trial. The study is evaluating the safety and feasibility of its NKR-2 T-cell therapy using T-cells with NKG2D receptor in cancer patients suffering from Acute Myeloid Leukemia (AML) or Multiple Myeloma .
No adverse safety signals have been observed so far for the nine patients already treated with NKR-2. Celyad is actively working on the recruitment of the two next patients for this new dose level and Celyad looks forward to the data that are expected in the next few months.
Medisun Holdings Limited is an associated company of National Investments. National Investments currently holds about 30% shareholding in Medisun. Medisun International Limited is a wholly-owned subsidiary of Medisun, and has invested in Celyad.
27/06/2016 11:22
National Inv says Celyad sees breakthrough in NKR-2 trial
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
